ABCC4,ABCC5 and SLC28A1 Polymorphisms: Host Genome on Responses of Chronic Hepatitis B Patients with Entecavir Treatment

European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167–185.

Santantonio T.A. , Fasano M. Chronic hepatitis B: advances in treatment. World J Hepatol 2014; 6: 284–292.

Fung J. , Lai C.L. , Seto W.K. , Yuen M F. Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. J Antimicrob Chemother 2011; 66: 2715–2725.

Ozaras R. , Khodor H. , Yetim N. Monotherapy for hepatitis B infection: a review of treatment options. Expert Rev Anti Infect Ther 2015; 13: 1457–1468.

Grossman I. ADME pharmacogenetics: current practices and future outlook. Expert Opin Drug Metab Toxicol 2009; 5: 449–462.

Errasti-Murugarren E. , Pastor-Anglada M. Drug transporter pharmacogenetics in nucleoside-based therapies. Pharmacogenomics 2010; 11: 809–841.

Borst P. , de Wolf C. , van de Wetering K. Multidrug resistance-associated proteins 3, 4, and 5. Pflugers Arch 2007; 453: 661–673.

Nakagawa H. , Toyoda Y. , Wakabayashi-Nakao K. , Tamaki H. , Osumi M. , Ishikawa T. Ubiquitin-mediated proteasomal degradation of ABC transporters: a new aspect of genetic polymorphisms and clinical impacts. J Pharm Sci 2011; 100: 3602–3619.

Janke D. , Mehralivand S. , Strand D. 6-mercaptopurine and 9- (2- phosphonyl-methoxyethyl) adenine (PMEA) transport altered by two missense mutations in the drug transporter gene ABCC5. Hum Mutat 2008; 29: 659–669.

Anderson P.L. , Lamba J. , Aquilante C.L. , Schuetz E. , Fletcher C V. Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. J Acquir Immune Defic Syndr 2006; 42: 441–449.

Wijnholds J. , Mol C.A. , van Deemter L. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci U S A 2000; 97: 7476–7481.

Smith K.M. , Ng A.M. , Yao S.Y. Electrophysiological characterization of a recombinant human Na+-coupled nucleoside transporter (hCNT1) produced in Xenopus oocytes. J Physiol 2004; 558: 807–823.

Woo H.I. , Kim K.K. , Choi H. Effect of genetic polymorphisms on therapeutic response and clinical outcomes in pancreatic cancer patients treated with gemcitabine. Pharmacogenomics 2012; 13: 1023–1035.

Kis O. , Robillard K. , Chan G.N. , Bendayan R. The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters. Trends Pharmacol Sci 2010; 31: 22–35.

Shi Y.Y. , He L. SHEsis, a powerful platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 2005; 15: 97–98.

Gradhand U. , Lang T. , Schaeffeler E. Variability in human hepatic MRP4 expression: influence of cholestasis and genotype. Pharmacogenomics J 2008; 8: 42–52.

Krishnamurthy P. , Schwab M. , Takenaka K. Transporter-mediated protection against thiopurine-induced hematopoietic toxicity. Cancer Res 2008; 68: 4983–4989.

Ban H. , Andoh A. , Imaeda H. The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease. J Gastroenterol 2010; 45: 1014–1021.

Rius M. , Nies A.T. , Hummel-Eisenbeiss J. , Jedlitschky G. , Keppler D. Cotransport of reduced glutathione with bile salts by MRP4 (ABCC5) localized to the basolateral hepatocyte membrane. Hepatology 2003; 38: 374–384.

van Aubel R.A. , Smeets P.H. , Peters J.G. , Bindels R.J. , Russel F.G. The MRP4/ABCC5 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol 2002; 13: 595–603.

Jedlitschky G. , Tirschmann K. , Lubenow L.E. The nucleotide transporter MRP4 (ABCC5) is highly expressed in human platelets and present in dense granules, indicating a role in mediator storage. Blood 2004; 104: 3603–3610.

Zelcer N. , Reid G. , Wielinga P. Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J 2003; 371: 361–367.

König J. , Hartel M. , Nies A.T. Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma. Int J Cancer 2005; 115: 359–367.

Mennone A. , Soroka C.J. , Cai S.Y. Mrp4-/- mice have an impaired cytoprotective response in obstructive cholestasis. Hepatology 2006; 43: 1013–1021.

Zollner G. , Wagner M. , Fickert P. Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis. Liver Int 2007; 27: 920–929.

Di Martino M.T. , Arbitrio M. , Leone E. Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study. Cancer Biol Ther 2011; 12: 780–787.

Kwan P. , Wong V. , Ng P.W. Gene-wide tagging study of the association between ABCC2, ABCC5 and ABCG2 genetic polymorphisms and multidrug resistance in epilepsy. Pharmacogenomics 2011; 12: 319–325.

Kool M. , de Haas M. , Scheffer G.L. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 1997; 57: 3537–3547.

Soo R.A. , Wang L.Z. , Ng S.S. Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients. Lung Cancer 2009; 63: 121–127.

Tekola-Ayele F. , Adeyemo A. , Aseffa A. Clinical and pharmacogenomic implications of genetic variation in a Southern Ethiopian population. Pharmacogenomics J 2015; 15: 101–108.